HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 386 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.45 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2019 | $694,000 | -72.8% | 39,141 | -70.0% | 0.03% | -67.0% |
Q1 2018 | $2,556,000 | -36.6% | 130,521 | -34.4% | 0.10% | -42.1% |
Q4 2017 | $4,032,000 | +97.4% | 199,021 | +69.2% | 0.18% | +71.2% |
Q3 2017 | $2,043,000 | +1289.8% | 117,621 | +922.3% | 0.10% | +1200.0% |
Q2 2017 | $147,000 | -84.8% | 11,505 | -88.3% | 0.01% | -86.2% |
Q4 2016 | $970,000 | +474.0% | 98,205 | +601.2% | 0.06% | +5.5% |
Q3 2016 | $169,000 | -33.2% | 14,005 | -52.3% | 0.06% | +323.1% |
Q2 2016 | $253,000 | -77.8% | 29,338 | -75.6% | 0.01% | -74.5% |
Q1 2016 | $1,138,000 | -38.6% | 120,238 | +12.4% | 0.05% | -42.0% |
Q4 2015 | $1,853,000 | -35.2% | 106,938 | -49.8% | 0.09% | -17.0% |
Q3 2015 | $2,861,000 | +873.1% | 213,078 | +1536.4% | 0.11% | +960.0% |
Q2 2015 | $294,000 | -60.6% | 13,021 | -82.8% | 0.01% | -74.4% |
Q2 2014 | $746,000 | -66.9% | 75,530 | -49.8% | 0.04% | -67.5% |
Q4 2013 | $2,257,000 | +300.2% | 150,601 | +112.2% | 0.12% | +566.7% |
Q2 2013 | $564,000 | – | 70,980 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Third Security, LLC | 7,048,282 | $126,799,000 | 27.23% |
First Light Asset Management, LLC | 1,630,591 | $29,334,000 | 5.01% |
SNYDER CAPITAL MANAGEMENT L P | 3,393,057 | $61,041,000 | 3.48% |
Bellevue Group AG | 7,663,956 | $137,874,000 | 2.67% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 307,633 | $5,531,000 | 2.52% |
Lombard Odier Asset Management (Switzerland) SA | 900,000 | $16,191,000 | 2.17% |
Elk Creek Partners, LLC | 654,362 | $11,772,000 | 2.02% |
DOHENY ASSET MANAGEMENT /CA | 127,110 | $2,254,000 | 1.79% |
Granite Investment Partners, LLC | 1,277,438 | $22,981,000 | 1.49% |
Amia Capital LLP | 69,409 | $1,249,000 | 1.11% |